{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:30:04Z","timestamp":1792737004601,"version":"4.5.0"},"reference-count":238,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":1461,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1038\/ki.2013.245","type":"journal-article","created":{"date-parts":[[2013,7,3]],"date-time":"2013-07-03T12:39:09Z","timestamp":1372855149000},"page":"667-681","source":"Crossref","is-referenced-by-count":28,"title":["Renal cell carcinoma: translational aspects of metabolism and therapeutic consequences"],"prefix":"10.1016","volume":"84","author":[{"given":"Oscar C.Y.","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2013.245_bb0010","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/nrurol.2010.46","article-title":"Epidemiology and risk factors for kidney cancer","volume":"7","author":"Chow","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1038\/ki.2013.245_bb0015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","article-title":"2004 WHO classification of the renal tumors of the adults","volume":"49","author":"Lopez-Beltran","year":"2006","journal-title":"Eur Urol"},{"key":"10.1038\/ki.2013.245_bb0020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1442-2042.2009.02302.x","article-title":"2009 update on the classification of renal epithelial tumors in adults","volume":"16","author":"Lopez-Beltran","year":"2009","journal-title":"Int J Urol"},{"key":"10.1038\/ki.2013.245_bb0025","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1038\/ki.2013.245_bb0030","first-page":"307","article-title":"Current role and future perspective of MRI for diagnosis and characterization of renal cell carcinoma","volume":"52","author":"Schoth","year":"2010","journal-title":"Panminerva Med"},{"key":"10.1038\/ki.2013.245_bb0035","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1146\/annurev.med.042808.171650","article-title":"Molecular diagnosis and therapy of kidney cancer","volume":"61","author":"Linehan","year":"2010","journal-title":"Annu Rev Med"},{"key":"10.1038\/ki.2013.245_bb0040","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1200\/JCO.2005.07.055","article-title":"Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience","volume":"23","author":"Patard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.245_bb0045","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"10.1038\/ki.2013.245_bb0050","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.pathol.2.010506.092049","article-title":"Von Hippel-Lindau disease","volume":"2","author":"Kaelin","year":"2007","journal-title":"Annu Rev Pathol"},{"key":"10.1038\/ki.2013.245_bb0055","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb0060","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jmg.37.5.348","article-title":"Familial clear cell renal cell carcinoma (FCRC): clinical features and mutation analysis of the VHL, MET, and CUL2 candidate genes","volume":"37","author":"Woodward","year":"2000","journal-title":"J Med Genet"},{"key":"10.1038\/ki.2013.245_bb0065","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"key":"10.1038\/ki.2013.245_bb0070","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"10.1038\/ki.2013.245_bb0075","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFa targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"10.1038\/ki.2013.245_bb0080","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"key":"10.1038\/ki.2013.245_bb0085","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"Bruick","year":"2001","journal-title":"Science"},{"key":"10.1038\/ki.2013.245_bb0090","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc704","article-title":"Hypoxia\u2014a key regulatory factor in tumour growth","volume":"2","author":"Harris","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/ki.2013.245_bb0095","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.semcancer.2008.11.009","article-title":"Regulation of cancer cell metabolism by hypoxia-inducible factor 1","volume":"19","author":"Semenza","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"10.1038\/ki.2013.245_bb0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cmet.2006.02.007","article-title":"Coming up for air: HIF-1 and mitochondrial oxygen consumption","volume":"3","author":"Simon","year":"2006","journal-title":"Cell Metab"},{"key":"10.1038\/ki.2013.245_bb0105","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1101\/sqb.2011.76.010678","article-title":"Regulation of metabolism by hypoxia-inducible factor 1","volume":"76","author":"Semenza","year":"2011","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10.1038\/ki.2013.245_bb0110","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cmet.2006.01.012","article-title":"HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption","volume":"3","author":"Papandreou","year":"2006","journal-title":"Cell Metab"},{"key":"10.1038\/ki.2013.245_bb0115","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.molcel.2009.09.006","article-title":"Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation","volume":"35","author":"Huang","year":"2009","journal-title":"Mol Cell"},{"key":"10.1038\/ki.2013.245_bb0120","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cmet.2009.08.015","article-title":"MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1\/2","volume":"10","author":"Chan","year":"2009","journal-title":"Cell Metab"},{"key":"10.1038\/ki.2013.245_bb0125","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1021\/bi1004798","article-title":"Human iron-sulfur cluster assembly, cellular iron homeostasis, and disease","volume":"49","author":"Ye","year":"2010","journal-title":"Biochemistry"},{"key":"10.1038\/ki.2013.245_bb0130","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.tig.2008.05.008","article-title":"Iron-sulfur cluster biogenesis and human disease","volume":"24","author":"Rouault","year":"2008","journal-title":"Trends Genet"},{"key":"10.1038\/ki.2013.245_bb0135","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/onc.2010.587","article-title":"Uncoupling hypoxia signaling from oxygen sensing in the liver results in hypoketotic hypoglycemic death","volume":"30","author":"Kucejova","year":"2011","journal-title":"Oncogene"},{"key":"10.1038\/ki.2013.245_bb0140","doi-asserted-by":"crossref","first-page":"e10345","DOI":"10.1371\/journal.pone.0010345","article-title":"MicroRNA-210 regulates mitochondrial free radical response to hypoxia and krebs cycle in cancer cells by targeting iron sulfur cluster protein ISCU","volume":"5","author":"Favaro","year":"2010","journal-title":"PLoS One"},{"key":"10.1038\/ki.2013.245_bb0145","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/nature11706","article-title":"How cancer metabolism is tuned for proliferation and vulnerable to disruption","volume":"491","author":"Schulze","year":"2012","journal-title":"Nature"},{"key":"10.1038\/ki.2013.245_bb0150","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1093\/hmg\/ddq206","article-title":"SDHA is a tumor suppressor gene causing paraganglioma","volume":"19","author":"Burnichon","year":"2010","journal-title":"Hum Mol Genet"},{"key":"10.1038\/ki.2013.245_bb0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1086\/321282","article-title":"Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma","volume":"69","author":"Astuti","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1038\/ki.2013.245_bb0160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/81551","article-title":"Mutations in SDHC cause autosomal dominant paraganglioma, type 3","volume":"26","author":"Niemann","year":"2000","journal-title":"Nat Genet"},{"key":"10.1038\/ki.2013.245_bb0165","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","article-title":"Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma","volume":"287","author":"Baysal","year":"2000","journal-title":"Science"},{"key":"10.1038\/ki.2013.245_bb0170","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/j.juro.2012.08.030","article-title":"Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer","volume":"188","author":"Ricketts","year":"2012","journal-title":"J Urol"},{"key":"10.1038\/ki.2013.245_bb0175","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.2932","article-title":"Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status","volume":"225","author":"Bardella","year":"2011","journal-title":"J Pathol"},{"key":"10.1038\/ki.2013.245_bb0180","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1126\/science.1175689","article-title":"SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma","volume":"325","author":"Hao","year":"2009","journal-title":"Science"},{"key":"10.1038\/ki.2013.245_bb0185","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.anndiagpath.2012.03.002","article-title":"Microscopic and nuclear morphometric findings of chromophobe renal cell carcinoma, renal oncocytoma, and tumor with overlapping histology","volume":"16","author":"Kim","year":"2012","journal-title":"Ann Diagn Pathol"},{"key":"10.1038\/ki.2013.245_bb0190","first-page":"238","article-title":"Mitochondrial remodeling in cancer metabolism and survival: potential for new therapies","volume":"1826","author":"Barbosa","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/ki.2013.245_bb0195","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PAP.0b013e31825c6bc6","article-title":"Succinate dehydrogenase-deficient tumors: diagnostic advances and clinical implications","volume":"19","author":"Barletta","year":"2012","journal-title":"Adv Anat Pathol"},{"key":"10.1038\/ki.2013.245_bb0200","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","article-title":"Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase","volume":"7","author":"Selak","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1038\/ki.2013.245_bb0205","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ccr.2005.06.015","article-title":"Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer","volume":"8","author":"Lee","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1038\/ki.2013.245_bb0210","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1039\/c0cs00203h","article-title":"Inhibition of 2-oxoglutarate dependent oxygenases","volume":"40","author":"Rose","year":"2011","journal-title":"Chem Soc Rev"},{"key":"10.1038\/ki.2013.245_bb0215","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nchembio0308-152","article-title":"Expanding chemical biology of 2-oxoglutarate oxygenases","volume":"4","author":"Loenarz","year":"2008","journal-title":"Nat Chem Biol"},{"key":"10.1038\/ki.2013.245_bb0220","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1476-4598-8-89","article-title":"Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells","volume":"8","author":"Cervera","year":"2009","journal-title":"Mol Cancer"},{"key":"10.1038\/ki.2013.245_bb0225","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1093\/hmg\/ddm275","article-title":"Succinate inhibition of alpha-ketoglutarate-dependent enzymes in a yeast model of paraganglioma","volume":"16","author":"Smith","year":"2007","journal-title":"Hum Mol Genet"},{"key":"10.1038\/ki.2013.245_bb0230","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1128\/MCB.01927-06","article-title":"Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells","volume":"27","author":"MacKenzie","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1038\/ki.2013.245_bb0235","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nature02488","article-title":"Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors","volume":"429","author":"He","year":"2004","journal-title":"Nature"},{"key":"10.1038\/ki.2013.245_bb0240","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MNH.0b013e328354a6bd","article-title":"Novel sensory signaling systems in the kidney","volume":"21","author":"Pluznick","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1038\/ki.2013.245_bb0245","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3389\/fendo.2012.00022","article-title":"The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions","volume":"3","author":"Ariza","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1038\/ki.2013.245_bb0250","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.1079605","article-title":"Architecture of succinate dehydrogenase and reactive oxygen species generation","volume":"299","author":"Yankovskaya","year":"2003","journal-title":"Science"},{"key":"10.1038\/ki.2013.245_bb0255","doi-asserted-by":"crossref","first-page":"7615","DOI":"10.1158\/0008-5472.CAN-06-0833","article-title":"Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability","volume":"66","author":"Slane","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0260","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0891-5849(00)00338-5","article-title":"Superoxides from mitochondrial complex III: the role of manganese superoxide dismutase","volume":"29","author":"Raha","year":"2000","journal-title":"Free Radic Biol Med"},{"key":"10.1038\/ki.2013.245_bb0265","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/MCB.01338-07","article-title":"Loss of the SdhB, but Not the SdhA, subunit of complex II triggers reactive oxygen species-dependent hypoxia-inducible factor activation and tumorigenesis","volume":"28","author":"Guzy","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1038\/ki.2013.245_bb0270","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/0008-5472.203.65.1","article-title":"A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis","volume":"65","author":"Ishii","year":"2005","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0275","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.bbabio.2006.05.015","article-title":"Redox stress is not essential for the pseudo-hypoxic phenotype of succinate dehydrogenase deficient cells","volume":"1757","author":"Selak","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/ki.2013.245_bb0280","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1464-410X.2011.10629.x","article-title":"Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials","volume":"108","author":"Coppin","year":"2011","journal-title":"BJU Int"},{"key":"10.1038\/ki.2013.245_bb0285","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000333470","article-title":"Combination therapy for renal cell cancer: what are possible options?","volume":"81","author":"Santos","year":"2011","journal-title":"Oncology"},{"key":"10.1038\/ki.2013.245_bb0290","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.245_bb0295","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.245_bb0300","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.245_bb0305","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1038\/ki.2013.245_bb0310","doi-asserted-by":"crossref","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","article-title":"Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206","volume":"26","author":"Rini","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.245_bb0315","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","article-title":"Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival","volume":"28","author":"Escudier","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.245_bb0320","doi-asserted-by":"crossref","first-page":"11410","DOI":"10.1074\/jbc.M111085200","article-title":"Paracrine and autocrine functions of neuronal vascular endothelial growth factor (VEGF) in the central nervous system","volume":"277","author":"Ogunshola","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2013.245_bb0325","doi-asserted-by":"crossref","first-page":"13264","DOI":"10.1073\/pnas.1101321108","article-title":"VEGF is essential for hypoxia-inducible factor-mediated neovascularization but dispensable for endothelial sprouting","volume":"108","author":"Oladipupo","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb0330","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.245_bb0335","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/ki.2013.245_bb0340","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/ki.2013.245_bb0345","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrm2672","article-title":"Molecular mechanisms of mTOR-mediated translational control","volume":"10","author":"Ma","year":"2009","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1038\/ki.2013.245_bb0350","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1038\/ki.2013.245_bb0355","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.2008.20.0766","article-title":"Targeting the mTOR signaling network for cancer therapy","volume":"27","author":"Meric-Bernstam","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.245_bb0360","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","article-title":"Defining the role of mTOR in cancer","volume":"12","author":"Guertin","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1038\/ki.2013.245_bb0365","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1242\/jcs.051011","article-title":"mTOR signaling at a glance","volume":"122","author":"Laplante","year":"2009","journal-title":"J Cell Sci"},{"key":"10.1038\/ki.2013.245_bb0370","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1038\/ki.2013.245_bb0375","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2007.10.002","article-title":"The biology of cancer: metabolic reprogramming fuels cell growth and proliferation","volume":"7","author":"DeBerardinis","year":"2008","journal-title":"Cell Metab"},{"key":"10.1038\/ki.2013.245_bb0380","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2013.245_bb0385","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev.cellbio.18.031502.133614","article-title":"Autoinhibitory domains: modular effectors of cellular regulation","volume":"18","author":"Pufall","year":"2002","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1038\/ki.2013.245_bb0390","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.transproceed.2008.10.006","article-title":"Temsirolimus in renal cell carcinoma","volume":"40","author":"Otto","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1038\/ki.2013.245_bb0395","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jjco\/hyq166","article-title":"Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1","volume":"41","author":"Tsukamoto","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1038\/ki.2013.245_bb0400","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/ki.2013.245_bb0405","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fonc.2012.00049","article-title":"Inter and intratumour heterogeneity: a barrier to individualized medical therapy in renal cell carcinoma?","volume":"2","author":"Fisher","year":"2012","journal-title":"Front Oncol"},{"key":"10.1038\/ki.2013.245_bb0410","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/sj.bjc.6605912","article-title":"How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine","volume":"103","author":"Gerlinger","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1038\/ki.2013.245_bb0415","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"key":"10.1038\/ki.2013.245_bb0420","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nrc2013","article-title":"Cancer as an evolutionary and ecological process","volume":"6","author":"Merlo","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/ki.2013.245_bb0425","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.cell.2012.02.025","article-title":"Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor","volume":"148","author":"Xu","year":"2012","journal-title":"Cell"},{"key":"10.1038\/ki.2013.245_bb0430","doi-asserted-by":"crossref","first-page":"127ps110","DOI":"10.1126\/scitranslmed.3003854","article-title":"Intratumor heterogeneity: seeing the wood for the trees","volume":"4","author":"Yap","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1038\/ki.2013.245_bb0435","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nrurol.2010.47","article-title":"The genetic basis of kidney cancer: a metabolic disease","volume":"7","author":"Linehan","year":"2010","journal-title":"Nat Rev Urol"},{"key":"10.1038\/ki.2013.245_bb0440","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ceb.2008.12.012","article-title":"VEGFs and receptors involved in angiogenesis versus lymphangiogenesis","volume":"21","author":"Lohela","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"10.1038\/ki.2013.245_bb0445","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/bies.20655","article-title":"Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer","volume":"29","author":"Quesada","year":"2007","journal-title":"Bioessays"},{"key":"10.1038\/ki.2013.245_bb0450","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cbf.1732","article-title":"An activator of PHD2, KRH102140, decreases angiogenesis via inhibition of HIF-1alpha","volume":"29","author":"Nepal","year":"2011","journal-title":"Cell Biochem Funct"},{"key":"10.1038\/ki.2013.245_bb0455","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1158\/1535-7163.MCT-05-0443","article-title":"Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding","volume":"5","author":"Jones","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/ki.2013.245_bb0460","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1158\/1078-0432.CCR-08-1918","article-title":"Dual degradation of aurora A and B kinases by the histone deacetylase inhibitor LBH589 induces G2-M arrest and apoptosis of renal cancer cells","volume":"15","author":"Cha","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0465","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/j.1464-410X.2011.10661.x","article-title":"Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine","volume":"109","author":"Audenet","year":"2012","journal-title":"BJU Int"},{"key":"10.1038\/ki.2013.245_bb0470","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/leu.2011.339","article-title":"The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia","volume":"26","author":"Willems","year":"2012","journal-title":"Leukemia"},{"key":"10.1038\/ki.2013.245_bb0475","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0480","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.juro.2011.09.053","article-title":"Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma","volume":"187","author":"Sukov","year":"2012","journal-title":"J Urol"},{"key":"10.1038\/ki.2013.245_bb0485","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.acthis.2012.10.009","article-title":"Clinicopathological, genetic, ultrastructural characterizations and prognostic factors of papillary renal cell carcinoma: new diagnostic and prognostic information","volume":"115","author":"Yu","year":"2013","journal-title":"Acta Histochem"},{"key":"10.1038\/ki.2013.245_bb0490","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3109\/00313021003785746","article-title":"Differential diagnosis of renal tumours with clear cell histology","volume":"42","author":"Reuter","year":"2010","journal-title":"Pathology"},{"key":"10.1038\/ki.2013.245_bb0495","first-page":"658767","article-title":"Familial renal cancer: molecular genetics and surgical management","volume":"2011","author":"Barrisford","year":"2011","journal-title":"Int J Surg Oncol"},{"key":"10.1038\/ki.2013.245_bb0500","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/ki.2013.245_bb0505","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","article-title":"Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas","volume":"16","author":"Schmidt","year":"1997","journal-title":"Nat Genet"},{"key":"10.1038\/ki.2013.245_bb0510","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2008.02.001","article-title":"Showering c-MET-dependent cancers with drugs","volume":"18","author":"Knudsen","year":"2008","journal-title":"Curr Opin Genet Dev"},{"key":"10.1038\/ki.2013.245_bb0515","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.tcb.2009.07.002","article-title":"Crosstalk in Met receptor oncogenesis","volume":"19","author":"Lai","year":"2009","journal-title":"Trends Cell Biol"},{"key":"10.1038\/ki.2013.245_bb0520","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrm3012","article-title":"MET signalling: principles and functions in development, organ regeneration and cancer","volume":"11","author":"Trusolino","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1038\/ki.2013.245_bb0525","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/era.09.43","article-title":"Targeting the Met signaling pathway in renal cancer","volume":"9","author":"Giubellino","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1038\/ki.2013.245_bb0530","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2214\/ajr.178.2.1780367","article-title":"Enhancement characteristics of papillary renal neoplasms revealed on triphasic helical CT of the kidneys","volume":"178","author":"Herts","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"10.1038\/ki.2013.245_bb0535","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1158\/0008-5472.CAN-04-3371","article-title":"Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2\/SPINT2 in papillary and clear cell renal cell carcinoma","volume":"65","author":"Morris","year":"2005","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0540","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/gm180","article-title":"Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics","volume":"2","author":"Morris","year":"2010","journal-title":"Genome Med"},{"key":"10.1038\/ki.2013.245_bb0545","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0002-9440(10)61757-9","article-title":"Familial cutaneous leiomyomatosis is a two-hit condition associated with renal cell cancer of characteristic histopathology","volume":"159","author":"Kiuru","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1038\/ki.2013.245_bb0550","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1073\/pnas.051633798","article-title":"Inherited susceptibility to uterine leiomyomas and renal cell cancer","volume":"98","author":"Launonen","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb0555","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2350-9-20","article-title":"The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency","volume":"9","author":"Bayley","year":"2008","journal-title":"BMC Med Genet"},{"key":"10.1038\/ki.2013.245_bb0560","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.juro.2007.01.155","article-title":"Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer","volume":"177","author":"Grubb","year":"2007","journal-title":"J Urol"},{"key":"10.1038\/ki.2013.245_bb0565","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.juro.2012.04.006","article-title":"Histopathology of surgically treated renal cell carcinoma: survival differences by subtype and stage","volume":"188","author":"Keegan","year":"2012","journal-title":"J Urol"},{"key":"10.1038\/ki.2013.245_bb0570","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1136\/jmg.2005.033506","article-title":"Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer","volume":"43","author":"Wei","year":"2006","journal-title":"J Med Genet"},{"key":"10.1038\/ki.2013.245_bb0575","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/PAS.0b013e31804375b8","article-title":"The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome","volume":"31","author":"Merino","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/ki.2013.245_bb0580","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1097\/PAS.0b013e31825ec16f","article-title":"Morphologic and molecular characteristics of uterine leiomyomas in hereditary leiomyomatosis and renal cancer (HLRCC) syndrome","volume":"37","author":"Sanz-Ortega","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/ki.2013.245_bb0585","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"key":"10.1038\/ki.2013.245_bb0590","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10545-011-9294-8","article-title":"Structural basis of fumarate hydratase deficiency","volume":"34","author":"Picaud","year":"2011","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/ki.2013.245_bb0595","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/nsb0895-654","article-title":"The multisubunit active site of fumarase C from Escherichia coli","volume":"2","author":"Weaver","year":"1995","journal-title":"Nat Struct Biol"},{"key":"10.1038\/ki.2013.245_bb0600","series-title":"Metabolism at a Glance","author":"Salway","year":"1999"},{"key":"10.1038\/ki.2013.245_bb0605","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000130569","article-title":"Mitochondrial and cytoplasmic forms of fumarate hydratase assigned to chromosome 1","volume":"16","author":"Craig","year":"1976","journal-title":"Cytogenet Cell Genet"},{"key":"10.1038\/ki.2013.245_bb0610","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/ajcn\/30.12.2083","article-title":"Urea biosynthesis I. The urea cycle and relationships to the citric acid cycle","volume":"30","author":"Shambaugh","year":"1977","journal-title":"Am J Clin Nutr"},{"key":"10.1038\/ki.2013.245_bb0615","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0272-6386(89)80209-4","article-title":"The purine nucleotide cycle activity in renal cortex and medulla","volume":"14","author":"Stepinski","year":"1989","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2013.245_bb0620","doi-asserted-by":"crossref","first-page":"e1000328","DOI":"10.1371\/journal.pbio.1000328","article-title":"Fumarase: a mitochondrial metabolic enzyme and a cytosolic\/nuclear component of the DNA damage response","volume":"8","author":"Yogev","year":"2010","journal-title":"PLoS Biol"},{"key":"10.1038\/ki.2013.245_bb0625","doi-asserted-by":"crossref","first-page":"41928","DOI":"10.1074\/jbc.M508718200","article-title":"Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1","volume":"280","author":"Lu","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2013.245_bb0630","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1074\/jbc.M608337200","article-title":"Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates","volume":"282","author":"Hewitson","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2013.245_bb0635","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.ccr.2011.09.006","article-title":"Renal cyst formation in Fh1-deficient mice is independent of the Hif\/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling","volume":"20","author":"Adam","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1038\/ki.2013.245_bb0640","doi-asserted-by":"crossref","first-page":"25772","DOI":"10.1074\/jbc.M109.019257","article-title":"Succination of thiol groups in adipose tissue proteins in diabetes: succination inhibits polymerization and secretion of adiponectin","volume":"284","author":"Frizzell","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2013.245_bb0645","doi-asserted-by":"crossref","first-page":"34219","DOI":"10.1074\/jbc.M703551200","article-title":"Succination of protein thiols during adipocyte maturation: a biomarker of mitochondrial stress","volume":"282","author":"Nagai","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2013.245_bb0650","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/oby.2011.340","article-title":"Tissue distribution of S-(2-succino)cysteine (2SC), a biomarker of mitochondrial stress in obesity and diabetes","volume":"20","author":"Thomas","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.1038\/ki.2013.245_bb0655","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1042\/BJ20112142","article-title":"Mitochondrial stress causes increased succination of proteins in adipocytes in response to glucotoxicity","volume":"445","author":"Frizzell","year":"2012","journal-title":"Biochem J"},{"key":"10.1038\/ki.2013.245_bb0660","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/10715762.2010.524643","article-title":"Succination of proteins in diabetes","volume":"45","author":"Frizzell","year":"2011","journal-title":"Free Radic Res"},{"key":"10.1038\/ki.2013.245_bb0665","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.celrep.2013.02.013","article-title":"Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency","volume":"3","author":"Ternette","year":"2013","journal-title":"Cell Rep"},{"key":"10.1038\/ki.2013.245_bb0670","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ccr.2011.08.024","article-title":"An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma","volume":"20","author":"Ooi","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1038\/ki.2013.245_bb0675","doi-asserted-by":"crossref","first-page":"18838","DOI":"10.1073\/pnas.1007387107","article-title":"Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals","volume":"107","author":"McMahon","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb0680","doi-asserted-by":"crossref","first-page":"13291","DOI":"10.1074\/jbc.R900010200","article-title":"The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress","volume":"284","author":"Nguyen","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1038\/ki.2013.245_bb0685","doi-asserted-by":"crossref","first-page":"6334","DOI":"10.1128\/MCB.00630-07","article-title":"Keap1 controls postinduction repression of the Nrf2-mediated antioxidant response by escorting nuclear export of Nrf2","volume":"27","author":"Sun","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1038\/ki.2013.245_bb0690","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1128\/MCB.01704-07","article-title":"Physiological significance of reactive cysteine residues of Keap1 in determining Nrf2 activity","volume":"28","author":"Yamamoto","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1038\/ki.2013.245_bb0695","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrc3278","article-title":"NRF2 and cancer: the good, the bad and the importance of context","volume":"12","author":"Sporn","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/ki.2013.245_bb0700","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cmet.2012.07.009","article-title":"Nrf2 orchestrates fuel partitioning for cell proliferation","volume":"16","author":"Hayes","year":"2012","journal-title":"Cell Metab"},{"key":"10.1038\/ki.2013.245_bb0705","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.pharmtox.43.100901.140229","article-title":"Regulatory mechanisms controlling gene expression mediated by the antioxidant response element","volume":"43","author":"Nguyen","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1038\/ki.2013.245_bb0710","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2011.10.005","article-title":"Succination of Keap1 and activation of Nrf2-dependent antioxidant pathways in FH-deficient papillary renal cell carcinoma type 2","volume":"20","author":"Kinch","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1038\/ki.2013.245_bb0715","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/0008-5472.CAN-12-3227","article-title":"CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma","volume":"73","author":"Ooi","year":"2013","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0720","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/B978-0-12-398339-8.00002-1","article-title":"The Keap1-Nrf2 cell defense pathway\u2014a promising therapeutic target?","volume":"63","author":"Copple","year":"2012","journal-title":"Adv Pharmacol"},{"key":"10.1038\/ki.2013.245_bb0725","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1365-2443.2010.01473.x","article-title":"Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution","volume":"16","author":"Taguchi","year":"2011","journal-title":"Genes Cells"},{"key":"10.1038\/ki.2013.245_bb0730","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1089\/ars.2010.3221","article-title":"Cancer chemoprevention mechanisms mediated through the Keap1-Nrf2 pathway","volume":"13","author":"Hayes","year":"2010","journal-title":"Antioxid Redox Signal"},{"key":"10.1038\/ki.2013.245_bb0735","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.tibs.2008.12.008","article-title":"NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer","volume":"34","author":"Hayes","year":"2009","journal-title":"Trends Biochem Sci"},{"key":"10.1038\/ki.2013.245_bb0740","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature10189","article-title":"Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis","volume":"475","author":"DeNicola","year":"2011","journal-title":"Nature"},{"key":"10.1038\/ki.2013.245_bb0745","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1158\/1078-0432.CCR-08-2822","article-title":"Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer","volume":"15","author":"Homma","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0750","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ccr.2012.05.016","article-title":"Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming","volume":"22","author":"Mitsuishi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1038\/ki.2013.245_bb0755","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2007.02.005","article-title":"Targeted inactivation of fh1 causes proliferative renal cyst development and activation of the hypoxia pathway","volume":"11","author":"Pollard","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1038\/ki.2013.245_bb0760","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cancergencyto.2009.08.018","article-title":"UOK 262 cell line, fumarate hydratase deficient (FH-\/FH-) hereditary leiomyomatosis renal cell carcinoma: in vitro and in vivo model of an aberrant energy metabolic pathway in human cancer","volume":"196","author":"Yang","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1038\/ki.2013.245_bb0765","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1535-7163.MCT-09-0824","article-title":"Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor","volume":"9","author":"Burgess","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/ki.2013.245_bb0770","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1158\/0008-5472.CAN-07-5960","article-title":"MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival","volume":"68","author":"Jin","year":"2008","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0775","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1158\/0008-5472.CAN-08-4889","article-title":"Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases","volume":"69","author":"Qian","year":"2009","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0780","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1634\/theoncologist.2012-0038","article-title":"Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?","volume":"17","author":"Albiges","year":"2012","journal-title":"Oncologist"},{"key":"10.1038\/ki.2013.245_bb0785","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1158\/1078-0432.CCR-09-1365","article-title":"Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors","volume":"16","author":"Gordon","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0790","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-09-1173","article-title":"ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity","volume":"9","author":"Munshi","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1038\/ki.2013.245_bb0795","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.245_bb0800","doi-asserted-by":"crossref","first-page":"ix258","DOI":"10.1093\/annonc\/mds399","article-title":"Genitourinary tumors, non-prostate","volume":"23","author":"Ravaud","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1038\/ki.2013.245_bb0805","first-page":"23","article-title":"Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma","volume":"23","author":"Koh","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1038\/ki.2013.245_bb0810","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10689-011-9491-5","article-title":"Hereditary leiomyomatosis and renal cell cancer presenting as metastatic kidney cancer at 18 years of age: implications for surveillance","volume":"11","author":"van Spaendonck-Zwarts","year":"2012","journal-title":"Fam Cancer"},{"key":"10.1038\/ki.2013.245_bb0815","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s10689-009-9306-0","article-title":"Hereditary leiomyomatosis and renal cell carcinoma: very early diagnosis of renal cancer in a paediatric patient","volume":"9","author":"Alrashdi","year":"2010","journal-title":"Fam Cancer"},{"key":"10.1038\/ki.2013.245_bb0820","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/jmg.2010.085068","article-title":"Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma","volume":"48","author":"Gardie","year":"2011","journal-title":"J Med Genet"},{"key":"10.1038\/ki.2013.245_bb0825","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1399-0004.2010.01486.x","article-title":"Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis","volume":"79","author":"Smit","year":"2011","journal-title":"Clin Genet"},{"key":"10.1038\/ki.2013.245_bb0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/path.2950","article-title":"Seeing the smoking gun: a sensitive and specific method to visualize loss of the tumour suppressor, fumarate hydratase, in human tissues","volume":"225","author":"Maxwell","year":"2011","journal-title":"J Pathol"},{"key":"10.1038\/ki.2013.245_bb0835","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.critrevonc.2012.07.001","article-title":"Cancer-associated genodermatoses: skin neoplasms as clues to hereditary tumor syndromes","volume":"85","author":"Ponti","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1038\/ki.2013.245_bb0840","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2007.13.3223","article-title":"Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma","volume":"26","author":"Choueiri","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.245_bb0845","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1002\/cncr.24864","article-title":"Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America","volume":"116","author":"Stadler","year":"2010","journal-title":"Cancer"},{"key":"10.1038\/ki.2013.245_bb0850","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/ncpuro0711","article-title":"Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer\u2014a distinct form of hereditary kidney cancer","volume":"4","author":"Sudarshan","year":"2007","journal-title":"Nat Clin Pract Urol"},{"key":"10.1038\/ki.2013.245_bb0855","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nature10363","article-title":"Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase","volume":"477","author":"Frezza","year":"2011","journal-title":"Nature"},{"key":"10.1038\/ki.2013.245_bb0860","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1158\/0008-5472.CAN-06-4571","article-title":"Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma","volume":"67","author":"Furge","year":"2007","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0865","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1097\/PAS.0b013e3181831e68","article-title":"Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases","volume":"32","author":"Amin","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/ki.2013.245_bb0870","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.urolonc.2007.07.015","article-title":"Pathobiology and prognosis of chromophobe renal cell carcinoma","volume":"26","author":"Klatte","year":"2008","journal-title":"Urol Oncol"},{"key":"10.1038\/ki.2013.245_bb0875","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.humpath.2004.09.011","article-title":"Expression of kidney-specific cadherin distinguishes chromophobe renal cell carcinoma from renal oncocytoma","volume":"36","author":"Mazal","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1038\/ki.2013.245_bb0880","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrc3365","article-title":"Mitochondria and cancer","volume":"12","author":"Wallace","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/ki.2013.245_bb0885","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.pathol.4.110807.092314","article-title":"Mitochondrial energetics and therapeutics","volume":"5","author":"Wallace","year":"2010","journal-title":"Annu Rev Pathol"},{"key":"10.1038\/ki.2013.245_bb0890","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/gcc.2870010112","article-title":"Alteration of mitochondrial DNA in human oncocytomas","volume":"1","author":"Welter","year":"1989","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1038\/ki.2013.245_bb0895","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1093\/hmg\/ddm371","article-title":"Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma","volume":"17","author":"Gasparre","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1038\/ki.2013.245_bb0900","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-07-4131","article-title":"Loss of complex I due to mitochondrial DNA mutations in renal oncocytoma","volume":"14","author":"Mayr","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1038\/ki.2013.245_bb0905","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S1470-2045(09)70188-3","article-title":"Birt-Hogg-Dube syndrome: diagnosis and management","volume":"10","author":"Menko","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1038\/ki.2013.245_bb0910","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1001\/archderm.1977.01640120042005","article-title":"Hereditary multiple fibrofolliculomas with trichodiscomas and acrochordons","volume":"113","author":"Birt","year":"1977","journal-title":"Arch Dermatol"},{"key":"10.1038\/ki.2013.245_bb0915","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1097\/00000478-200212000-00002","article-title":"Renal tumors in the Birt-Hogg-Dube syndrome","volume":"26","author":"Pavlovich","year":"2002","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/ki.2013.245_bb0920","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2214\/AJR.04.1475","article-title":"Birt-Hogg-Dube syndrome: a rare cause of pulmonary cysts","volume":"185","author":"Souza","year":"2005","journal-title":"AJR Am J Roentgenol"},{"key":"10.1038\/ki.2013.245_bb0925","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1097\/01.ju.0000154629.45832.30","article-title":"Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome","volume":"173","author":"Pavlovich","year":"2005","journal-title":"J Urol"},{"key":"10.1038\/ki.2013.245_bb0930","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1399-0004.2009.01159.x","article-title":"Early onset of renal cancer in a family with Birt-Hogg-Dube syndrome","volume":"75","author":"Kluijt","year":"2009","journal-title":"Clin Genet"},{"key":"10.1038\/ki.2013.245_bb0935","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1038\/sj.onc.1204703","article-title":"Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2","volume":"20","author":"Khoo","year":"2001","journal-title":"Oncogene"},{"key":"10.1038\/ki.2013.245_bb0940","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1086\/430842","article-title":"Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome","volume":"76","author":"Schmidt","year":"2005","journal-title":"Am J Hum Genet"},{"key":"10.1038\/ki.2013.245_bb0945","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/jmg.2007.054304","article-title":"BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports","volume":"45","author":"Toro","year":"2008","journal-title":"J Med Genet"},{"key":"10.1038\/ki.2013.245_bb0950","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/modpathol.3800152","article-title":"Expression of Birt-Hogg-Dube gene mRNA in normal and neoplastic human tissues","volume":"17","author":"Warren","year":"2004","journal-title":"Mod Pathol"},{"key":"10.1038\/ki.2013.245_bb0955","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1535-6108(02)00104-6","article-title":"Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome","volume":"2","author":"Nickerson","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1038\/ki.2013.245_bb0960","doi-asserted-by":"crossref","first-page":"15552","DOI":"10.1073\/pnas.0603781103","article-title":"Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling","volume":"103","author":"Baba","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb0965","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1182\/blood-2012-02-410407","article-title":"The folliculin-FNIP1 pathway deleted in human Birt-Hogg-Dube syndrome is required for murine B-cell development","volume":"120","author":"Baba","year":"2012","journal-title":"Blood"},{"key":"10.1038\/ki.2013.245_bb0970","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1136\/jclinpath-2012-201200","article-title":"Birt-Hogg-Dube syndrome: clinicopathological features of the lung","volume":"66","author":"Furuya","year":"2012","journal-title":"J Clin Pathol"},{"key":"10.1038\/ki.2013.245_bb0975","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/jnci\/djm288","article-title":"Kidney-targeted Birt-Hogg-Dube gene inactivation in a mouse model: Erk1\/2 and Akt-mTOR activation, cell hyperproliferation, and polycystic kidneys","volume":"100","author":"Baba","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1038\/ki.2013.245_bb0980","first-page":"1407","article-title":"Review of renal oncocytosis (multiple oncocytic lesions) with focus on clinical and pathobiological aspects","volume":"27","author":"Kuroda","year":"2012","journal-title":"Histol Histopathol"},{"key":"10.1038\/ki.2013.245_bb0985","series-title":"Fam Cancer","article-title":"Birt-Hogg-Dube syndrome: from gene discovery to molecularly targeted therapies","author":"Schmidt","year":"2012"},{"key":"10.1038\/ki.2013.245_bb0990","doi-asserted-by":"crossref","first-page":"e3581","DOI":"10.1371\/journal.pone.0003581","article-title":"Deficiency of FLCN in mouse kidney led to development of polycystic kidneys and renal neoplasia","volume":"3","author":"Chen","year":"2008","journal-title":"PLoS One"},{"key":"10.1038\/ki.2013.245_bb0995","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3816\/CGC.2006.n.005","article-title":"Chemotherapy for non-clear-cell renal cell carcinoma","volume":"4","author":"David","year":"2006","journal-title":"Clin Genitourin Cancer"},{"key":"10.1038\/ki.2013.245_bb1000","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/PAS.0b013e3181829ed5","article-title":"Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid change","volume":"33","author":"Dhillon","year":"2009","journal-title":"Am J Surg Pathol"},{"key":"10.1038\/ki.2013.245_bb1005","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1016\/j.juro.2009.08.049","article-title":"Effect of collecting duct histology on renal cell cancer outcome","volume":"182","author":"Wright","year":"2009","journal-title":"J Urol"},{"key":"10.1038\/ki.2013.245_bb1010","first-page":"180","article-title":"Mucinous tubular and spindle cell carcinoma of the kidney with sarcomatoid differentiation","volume":"1","author":"Simon","year":"2008","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1038\/ki.2013.245_bb1015","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s11912-011-0159-y","article-title":"Non-clear cell renal cell carcinoma: how new biological insight may lead to new therapeutic modalities","volume":"13","author":"Bex","year":"2011","journal-title":"Curr Oncol Rep"},{"key":"10.1038\/ki.2013.245_bb1020","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.juro.2007.01.063","article-title":"Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Genitales) study","volume":"177","author":"Oudard","year":"2007","journal-title":"J Urol"},{"key":"10.1038\/ki.2013.245_bb1025","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1200\/JCO.2010.30.1457","article-title":"Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to sunitinib","volume":"28","author":"Larkin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1038\/ki.2013.245_bb1030","doi-asserted-by":"crossref","first-page":"6848","DOI":"10.1158\/0008-5472.CAN-11-1745","article-title":"Generation of a mouse model of Von Hippel-Lindau kidney disease leading to renal cancers by expression of a constitutively active mutant of HIF1alpha","volume":"71","author":"Fu","year":"2011","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb1035","doi-asserted-by":"crossref","first-page":"8762","DOI":"10.1073\/pnas.151033798","article-title":"A germ-line Tsc1 mutation causes tumor development and embryonic lethality that are similar, but not identical to, those caused by Tsc2 mutation in mice","volume":"98","author":"Kobayashi","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb1040","doi-asserted-by":"crossref","first-page":"10179","DOI":"10.1158\/0008-5472.CAN-05-2688","article-title":"Induction of renal tumorigenesis with elevated levels of somatic loss of heterozygosity in Tsc1+\/- mice on a Blm-deficient background","volume":"65","author":"Wilson","year":"2005","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb1045","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1093\/hmg\/ddi190","article-title":"A mouse model of tuberous sclerosis 1 showing background specific early post-natal mortality and metastatic renal cell carcinoma","volume":"14","author":"Wilson","year":"2005","journal-title":"Hum Mol Genet"},{"key":"10.1038\/ki.2013.245_bb1050","first-page":"1206","article-title":"Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice","volume":"59","author":"Kobayashi","year":"1999","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb1055","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1172\/JCI7319","article-title":"Tsc2(+\/-) mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background","volume":"104","author":"Onda","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1038\/ki.2013.245_bb1060","doi-asserted-by":"crossref","first-page":"18722","DOI":"10.1073\/pnas.0908853106","article-title":"Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2","volume":"106","author":"Hasumi","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb1065","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/ng0195-70","article-title":"A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer","volume":"9","author":"Kobayashi","year":"1995","journal-title":"Nat Genet"},{"key":"10.1038\/ki.2013.245_bb1070","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/emboj.2008.96","article-title":"pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation","volume":"27","author":"Frew","year":"2008","journal-title":"EMBO J"},{"key":"10.1038\/ki.2013.245_bb1075","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-05-3241","article-title":"Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor","volume":"66","author":"Rankin","year":"2006","journal-title":"Cancer Res"},{"key":"10.1038\/ki.2013.245_bb1080","doi-asserted-by":"crossref","first-page":"e7987","DOI":"10.1371\/journal.pone.0007987","article-title":"Sdhd and SDHD\/H19 knockout mice do not develop paraganglioma or pheochromocytoma","volume":"4","author":"Bayley","year":"2009","journal-title":"PLoS One"},{"key":"10.1038\/ki.2013.245_bb1085","doi-asserted-by":"crossref","first-page":"10933","DOI":"10.1128\/MCB.24.24.10933-10940.2004","article-title":"The mitochondrial SDHD gene is required for early embryogenesis, and its partial deficiency results in persistent carotid body glomus cell activation with full responsiveness to hypoxia","volume":"24","author":"Piruat","year":"2004","journal-title":"Mol Cell Biol"},{"key":"10.1038\/ki.2013.245_bb1090","series-title":"Transgenic Mouse - Methods and Protocols","author":"Redi","year":"2011"},{"key":"10.1038\/ki.2013.245_bb1095","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"key":"10.1038\/ki.2013.245_bb1100","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"key":"10.1038\/ki.2013.245_bb1105","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"key":"10.1038\/ki.2013.245_bb1110","doi-asserted-by":"crossref","first-page":"10877","DOI":"10.1073\/pnas.89.22.10877","article-title":"Definition of a tumor suppressor locus within human chromosome 3p21-p22","volume":"89","author":"Killary","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb1115","series-title":"Comparative Anatomy and Histology: A Mouse and Human Atlas","author":"Treuting","year":"2012"},{"key":"10.1038\/ki.2013.245_bb1120","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng.1014","article-title":"Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma","volume":"44","author":"Guo","year":"2011","journal-title":"Nat Genet"},{"key":"10.1038\/ki.2013.245_bb1125","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.1231733","article-title":"Cancer. The utility of mouse models in post-GWAS research","volume":"338","author":"Lewis","year":"2012","journal-title":"Science"},{"key":"10.1038\/ki.2013.245_bb1130","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1210\/jc.2012-2356","article-title":"Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas","volume":"97","author":"Ayala-Ramirez","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/ki.2013.245_bb1135","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq029","article-title":"Targeted agents in metastatic Xp11 translocation\/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network","volume":"21","author":"Malouf","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1038\/ki.2013.245_bb1140","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1073\/pnas.98.4.1583","article-title":"Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor","volume":"98","author":"Haase","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb1145","doi-asserted-by":"crossref","first-page":"F1023","DOI":"10.1152\/ajprenal.90209.2008","article-title":"Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis","volume":"295","author":"Kimura","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1038\/ki.2013.245_bb1150","doi-asserted-by":"crossref","first-page":"e31120","DOI":"10.1371\/journal.pone.0031120","article-title":"ELR510444 inhibits tumor growth and angiogenesis by abrogating HIF activity and disrupting microtubules in renal cell carcinoma","volume":"7","author":"Carew","year":"2012","journal-title":"PLoS One"},{"key":"10.1038\/ki.2013.245_bb1155","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/bjc.2011.55","article-title":"Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model","volume":"104","author":"Yuen","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1038\/ki.2013.245_bb1160","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.eururo.2010.11.043","article-title":"Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma","volume":"59","author":"Karam","year":"2011","journal-title":"Eur Urol"},{"key":"10.1038\/ki.2013.245_bb1165","doi-asserted-by":"crossref","first-page":"e31034","DOI":"10.1371\/journal.pone.0031034","article-title":"Renal tubular HIF-2alpha expression requires VHL inactivation and causes fibrosis and cysts","volume":"7","author":"Schietke","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1038\/ki.2013.245_bb1170","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1093\/hmg\/ddp398","article-title":"Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1","volume":"18","author":"Zhou","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1038\/ki.2013.245_bb1175","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nm.1865","article-title":"An efficient and versatile system for acute and chronic modulation of renal tubular function in transgenic mice","volume":"14","author":"Traykova-Brauch","year":"2008","journal-title":"Nat Med"},{"key":"10.1038\/ki.2013.245_bb1180","doi-asserted-by":"crossref","first-page":"17198","DOI":"10.1073\/pnas.0407651101","article-title":"Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele","volume":"101","author":"Graveel","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/ki.2013.245_bb1185","doi-asserted-by":"crossref","first-page":"e13586","DOI":"10.1371\/journal.pone.0013586","article-title":"Germline met mutations in mice reveal mutation- and background-associated differences in tumor profiles","volume":"5","author":"Graveel","year":"2010","journal-title":"PLoS One"},{"key":"10.1038\/ki.2013.245_bb1190","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/onc.2009.14","article-title":"The role of the Birt-Hogg-Dube protein in mTOR activation and renal tumorigenesis","volume":"28","author":"Hartman","year":"2009","journal-title":"Oncogene"},{"key":"10.1038\/ki.2013.245_bb1195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.abb.2006.03.005","article-title":"S-(2-Succinyl)cysteine: a novel chemical modification of tissue proteins by a Krebs cycle intermediate","volume":"450","author":"Alderson","year":"2006","journal-title":"Arch Biochem Biophys"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815560390?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815560390?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T21:22:44Z","timestamp":1688332964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815560390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":238,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0085253815560390"],"URL":"https:\/\/doi.org\/10.1038\/ki.2013.245","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]}}}